Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody

Clinical Neurology

Volumn 51, Issue 10, 2011, Pages 761-764

  Motoyama, Rie ^a   Yamakawa, Kentaro ^a   Suzuki, Seiko ^b   Kusunoki, Susumu ^b   Tanaka, Masami ^a  

^a UTANO NATIONAL HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Demyelinating neuropathy; Myelin associated glycoprotein; Rituximab; Sensory ataxia; Two point discrimination

Indexed keywords

IMMUNOGLOBULIN M; MYELIN ASSOCIATED GLYCOPROTEIN; PROTEIN ANTIBODY; RITUXIMAB;

ABNORMAL SENSATION; ADULT; ANTIBODY TITER; AREFLEXIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEMYELINATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERALGESIA; HYPESTHESIA; LIMB WEAKNESS; MALE; MULTIPLE CYCLE TREATMENT; POLYNEUROPATHY; SYMPTOM; TREATMENT OUTCOME; UNSTEADINESS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; DEMYELINATING DISEASES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; POLYNEUROPATHIES;

EID: 80955124693     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: 10.5692/clinicalneurol.51.761     Document Type: Article

References (16)

1. Dalakas MC. Pathogenesis and treatment of anti-MAG neuropathy. Curr Treat Opt Neurol 2010;12:71-83.
2. McGarry RC, Helfand SL, Quarles RH, et al. Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature 1983;306:376-378. (Pubitemid 14242748)
3. Sato S, Baba H, Tanaka M, et al. Antigenic determinant shared between myelin-associated glycoprotein from human brain and natural killer cells. Biomed Res 1983;4:489-494. (Pubitemid 14224843)
4. Ilyas AA, Gu Y, Dalakas MC, et al. Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol 2008;193:87-93.
5. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40: 792-795. (Pubitemid 26415192)
6. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999;52:1701-1704. (Pubitemid 29220654)
7. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611-615. (Pubitemid 36523521)
8. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and antimyelin associated glycoprotein immunoglobulin. J Periph Nerv Syst 2007;12:102-107. (Pubitemid 46906332)
9. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009;65:286-293.
10. Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. Pharmacol Ther 2006;112:57-70. (Pubitemid 44301485)
11. Merkies ISJ, Schmitz PIM, van der Meché FGA, et al. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 2000;54:943-949. (Pubitemid 30111356)
12. Latov N, Renaud S. Effector mechanisms in anti-MAG antibody-mediated and other demyelinating neuropathies. J Neurol Sci 2004;220:127-129. (Pubitemid 38622112)
13. Gironi M, Saresella M, Marventano I, et al. Distinct cytokine patterns associated with different forms of chronic dysimmune neuropathy. Muscle Nerve 2010;42:864-870.
14. Benedetti L, Briani C, Franciotta D, et al. Long term effect of rituximab in anti-MAG polyneuropathy. Neurology 2008;71:1742-1744.